![]() |
市場調查報告書
商品編碼
1504198
藥物安全檢測市場規模,佔有率,預測,趨勢分析:報價環,不同階段,各治療領域,各終端用戶-2031年前的全球預測Pharmacovigilance Market Size, Share, Forecast, & Trends Analysis by Offering (Software, Services ), Phase, Therapeutic Area, End User - Global Forecast to 2031 |
藥物警戒市場預計到 2031 年將達到 180.5 億美元,2024 年至 2031 年複合年增長率為 10.7%。
經過廣泛的二級和一級研究以及對藥物警戒市場情景的詳細分析,本報告對關鍵行業的驅動因素、限制因素、課題和機會進行了分析。藥物警戒市場的成長主要是由藥物毒性發生率上升、嚴格的監管框架、藥物研究支出的增加、新藥開發需求的增加以及對醫療器材安全性的日益關注所推動的。然而,藥物警戒服務的高成本限制了中小企業的採用,限制了該市場的成長。
此外,技術先進的軟體的引入、對藥物副作用的認識不斷增強、需要組合藥物的治療方法以及藥物警戒服務外包的增加正在推動該市場利益相關者的成長,預計將帶來機會。然而,資料安全風險和熟練藥物警戒專業人員的短缺給市場成長帶來了重大課題。
(註:提供前 5 名公司 SWOT 分析)
Pharmacovigilance Market Size, Share, Forecast, & Trends Analysis by Offering (Software [Adverse Event Reporting, Issue Tracking, Drug Safety Audit], Services [Spontaneous Reporting, Case Logging]), Phase, Therapeutic Area, End User-Global Forecast to 2031
The pharmacovigilance market is projected to reach $18.05 billion by 2031 at a CAGR of 10.7% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the pharmacovigilance market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the pharmacovigilance market is mainly driven by the rising incidence of drug toxicity, stringent regulatory frameworks, increasing pharmaceutical research spending, rising need for new drug development, and the increasing focus on medical device safety. However, the high costs of pharmacovigilance services limit their adoption among small & mid-sized companies, restraining the growth of this market.
Furthermore, the introduction of technologically advanced software, growing awareness regarding adverse drug reactions, therapeutic approaches requiring a combination of drugs, and the increasing outsourcing of pharmacovigilance services are expected to generate growth opportunities for the stakeholders in this market. However, data security risks and the shortage of skilled pharmacovigilance professionals pose major challenges for market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the pharmacovigilance market are IQVIA (U.S.), Cognizant Technology Solutions Corporation (U.S.), Linical Co., Ltd (U.S.), International Business Machines Corporation (U.S.), Laboratory Corporation of America Holdings (U.S.), ICON plc (Ireland), Parexel International (U.S.), Wipro Limited (India), Sanofi S.A. (France), Pharmaceutical Product Development Inc. (a subsidiary of Thermo Fisher Scientific Inc.) (U.S.), Capgemini SE (France), Syneos Health (U.S.), ArisGlobal (U.S.), Ennov (France), EXTEDO GmbH (Germany), Oracle Corporation (U.S.), Sparta Systems Inc. (U.S.), United BioSource, LLC (UBC) (U.S.), and AB Cube S.A.S. (France).
Based on offering, in 2024, the services segment is expected to account for the largest share of over 97.6% of the pharmacovigilance market. The services segment is further segmented into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, EHR mining, and other services based on type. The increasing number of molecules in clinical development and the growing importance of drug safety are driving the outsourcing of pharmacovigilance services. Additionally, the need for regulatory compliance, rising drug complexity, globalization of clinical trials, and increasing awareness about drug safety are further contributing to the segment's growth.
Based on drug development phase, the Phase IV segment is projected to witness the highest growth rate during the forecast period 2024-2031. The study design and sample sizes are larger and more complex in Phase IV as the drug is tested post-approval; hence, the demand for pharmacovigilance services is higher in Phase IV due to the need for efficient management and data analysis. Additionally, the high complexity of Phase IV is increasing the adoption of pharmacovigilance services for the efficient management of clinical trials.
Based on therapeutic area, in 2024, the oncology segment is expected to account for the largest share of the pharmacovigilance market. According to GLOBOCAN, the prevalence of cancer is expected to reach 32.64 million in 2045 from 19.98 million in 2022. The rising prevalence of cancer is increasing the demand for newer therapies and drugs, driving the adoption of pharmacovigilance software and services. Additionally, the availability of funding for oncology, life sciences & healthcare research, the increasing demand for personalized therapies, and the high cancer incidence necessitating newer therapies to be launched in the market are contributing to segment growth.
Based on end user, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the pharmacovigilance market. The large market share of this segment is attributed to the increasing R&D investments by pharmaceutical & biotechnology companies and rising funding for pharmaceutical research. Additionally, changing regulations across the pharmaceutical industry are increasing the adoption of pharmacovigilance tools to support regulatory submissions for drug approval, timely & accurate reporting of ADRs, and ensuring compliance with changing regulatory requirements.
An in-depth analysis of the geographical scenario of the global pharmacovigilance market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.
In 2024, North America is expected to account for the largest share of over 44.3% of the pharmacovigilance market. The large share of the regional market is attributed to the presence of key players, advanced infrastructure and resources supporting research & development, the large number of clinical trials and drug approvals, and increased reporting of adverse drug events in the region.
Pharmacovigilance Market Assessment-by Offering
Note: Other Functionalities comprise reporting and analytics, case management, and signal management.
Note: Other Services comprise case processing, signal management, regulatory intelligence, and consulting services.
Pharmacovigilance Market Assessment-by Drug Development Phase
Pharmacovigilance Market Assessment-by Therapeutic Area
Pharmacovigilance Market Assessment-by End User
Note: Other End Users comprise CROs and BPOs.
Pharmacovigilance Market Assessment-by Geography
(Note: SWOT analysis will be provided for the top 5 companies.)